Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyCentene allogeneic progenitor cell therapy Coverag…
    Ask Trek AI about this page
    CurrentCentenePolicy CP.MP.249

    Allogeneic Hematopoietic Progenitor Cell Therapy

    Customize your policy alerts

    Sign up for Centene Policy CP.MP.249 alerts

    Get alerted when Policy CP.MP.249 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity criteria for use of Omisirge (omidubicel) and RegeneCyte (HPC Cord Blood) for non‑Medicare Centene-affiliated health plans; who may qualify and under what conditions.

    Policy Summary
    PayerCentene
    PolicyAllogeneic Hematopoietic Progenitor Cell Therapy
    Policy CodePolicy CP.MP.249
    Change TypeAdded RegeneCyterevised Omisirge pediatric indication
    Effective Date
    Last ReviewJan 26, 2026
    Next Review Date
    Key ActionObtain prior authorization and document that the member meets the policy's age- and indication-specific medical necessity criteria.
    SourceLink
    POLICY UPDATE CHANGES

    RegeneCyte (HPC Cord Blood) criteria were added to the policy as Criteria II.

    Criteria I updated to include severe aplastic anemia as a medically necessary indication for Omisirge.

    Added note referring Medicare criteria to separate Medicare policy MC.CP.MP.249 and specified 'non‑Medicare' health plans.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥12
    min age Omisirge (malignancy)
    ≥6min age Omisirge (aplastic anemia)
    87% vs 83%neutrophil recovery (Omisirge vs CB)
    12d vs 22dmean time to neutrophil recovery
    Omisirge 2023; RegeneCyte 2024regulatory milestones

    Medical Necessity and Coverage Criteria

    Medical necessity criteria — Omisirge and RegeneCyte

    Covered when ALL of the following are met for each listed product-specific criteria:

    Omisirge - Hematologic malignancies: Member/enrollee is >= 12 years of age AND member/enrollee is planned for an umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection AND request is for one administration post-myeloablative conditioning.age >= 12

    Omisirge is FDA‑approved for this population and demonstrated faster neutrophil recovery (mean ~12 days) and fewer infections versus standard cord blood transplantation.

    Omisirge - Severe aplastic anemia: Member/enrollee is >= 6 years of age AND request is for one administration following reduced intensity conditioning.age >= 6

    FDA approval and single‑arm study data support neutrophil engraftment and transfusion independence in most patients.

    RegeneCyte (HPC Cord Blood): Member/enrollee is planned for an unrelated donor hematopoietic progenitor cell transplantation procedure AND an appropriate preparative regimen for hematopoietic and immunologic reconstitution will be used in conjunction with the transplantation procedure AND member/enrollee has a disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.

    RegeneCyte (HPC Cord Blood) is indicated to support hematopoietic reconstitution; effectiveness demonstrated across clinical studies.

    This policy applies to non‑Medicare Centene‑affiliated health plans. Medicare members should be referred to MC.CP.MP.249 for Medicare‑specific coverage criteria and operational requirements.

    Inclusion or exclusion of codes in this policy does not by itself indicate coverage. Codes referenced are for informational purposes only; providers must consult current professional coding guidance before submitting claims and confirm that the requested services meet the policy's clinical medical necessity criteria.

    Referenced Codes and Key Study Metrics

    Referenced codesmixed
    J3590Unclassified biologics.
    C9399Unclassified drugs or biologicals.
    Neutrophil recovery time and study metrics
    Omisirge — mean/median time to neutrophil recovery87% of subjects achieved neutrophil recovery in an average of 12 days (Omisirge) vs 83% in an average of 22 days (standard cord blood transplantation).
    Cord blood (historical/standard CBT) — mean/median timeNeutrophil recovery achieved in an average/median of 22–27 days in cord blood transplantation (22 days in randomized study; median 27 days in COBLT).
    RegeneCyte — median time to neutrophil recovery (COBLT)In the COBLT study supporting RegeneCyte, among 324 patients the median time to neutrophil recovery was 27 days (76% achieved neutrophil recovery by day 42).
    Clinical outcomes linked to faster recoveryOmisirge recipients had fewer bacterial or fungal infections, fewer ICU days, shorter total hospital length of stay, and fewer deaths within first 100 days compared with cord blood transplantation recipients.

    Prior Authorization, Documentation, and Denial Triggers

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Omisirge (omidubicel) and RegeneCyte. Submit supporting clinical documentation that demonstrates the member meets the applicable medical necessity criteria in this policy prior to administration.

    • Prior authorization required for Omisirge and RegeneCyte
    • Include indication, age, conditioning regimen, and planned transplant details
    Documentation Required

    Provider Documentation Requirements

    Providers must document and submit clinical records that clearly show the member meets the specific criteria for the requested product (age thresholds, diagnosis, planned conditioning regimen, and whether administration is post-myeloablative or following reduced intensity conditioning). Ensure documentation of the unrelated donor transplant plan for RegeneCyte and the single administration request for Omisirge when applicable.

    Preparative Regimens and Use Context

    RegimenApplicability / Notes
    Reduced‑intensity preparative regimens
    Permitted when RegeneCyte or Omisirge is used in indications that specify reduced intensity conditioning (Omisirge coverage for severe aplastic anemia requires one administration following reduced intensity conditioning; RegeneCyte requires an appropriate preparative regimen — myeloablative or reduced intensity — in conjunction with unrelated donor transplantation).

    Indication / Line of Therapy Rules

    Salvage

    Salvage use for transplantation: Use is limited to patients meeting the product‑specific transplantation criteria above (e.g., Omisirge for planned umbilical cord blood transplantation after myeloablative conditioning or RegeneCyte for unrelated donor hematopoietic progenitor cell transplantation) and when an appropriate preparative regimen will be used; requests outside these transplantation‑related indications do not meet salvage criteria.

    Policy ties use to transplantation procedures rather than general salvage therapy.

    Key Definitions

    Myeloablative conditioning (MAC) — definition
    DefinitionMyeloablative conditioning (MAC) is a regimen, single agent or combination, anticipated to destroy hematopoietic cells in the bone marrow; extensive pancytopenia occurs within one to three weeks after administration and is typically irreversible.
    Clinical effectMAC causes destruction (ablation) of marrow stem cells that produce new blood cells, leading to prolonged/irreversible pancytopenia.
    Typical timing of pancytopeniaExtensive pancytopenia occurs within 1–3 weeks after MAC administration.
    Allogeneic hematopoietic progenitor cell therapy — definition
    DefinitionAllogeneic hematopoietic progenitor cell therapy: donor-derived umbilical cord blood–derived cell products (e.g., Omisirge, RegeneCyte) intended to accelerate hematopoietic recovery following transplantation and support hematopoietic and immunologic reconstitution.

    Clinical and Product Background

    Allogeneic hematopoietic cell transplantation (HCT) uses donor‑derived hematopoietic progenitor cells after a preparative regimen (myeloablative or reduced intensity) to restore hematopoiesis and immune function. Myeloablative conditioning is intended to ablate the recipient’s marrow, producing profound pancytopenia prior to donor cell infusion. Donor‑derived cord blood–based products (for example, Omisirge and RegeneCyte) are cellular therapies developed to accelerate hematopoietic recovery after transplantation and to reduce complications such as infection related to prolonged neutropenia. This policy defines the non‑Medicare medical necessity criteria under which these allogeneic hematopoietic progenitor cell therapies may be covered when used in conjunction with an appropriate preparative regimen and transplant procedure.

    Policy Summary
    PayerCentene
    PolicyAllogeneic Hematopoietic Progenitor Cell Therapy
    Policy CodePolicy CP.MP.249
    Change TypeAdded RegeneCyterevised Omisirge pediatric indication
    Effective Date
    Last ReviewJan 26, 2026
    Next Review Date
    Key ActionObtain prior authorization and document that the member meets the policy's age- and indication-specific medical necessity criteria.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaReferenced Codes and Key Study MetricsPrior Authorization, Documentation, and Denial TriggersPreparative Regimens and Use ContextIndication / Line of Therapy RulesKey DefinitionsClinical and Product Background
  1. For Omisirge: age and indication (hematologic malignancy ≥ 12 years or severe aplastic anemia ≥ 6 years), planned umbilical cord blood transplantation, and conditioning type (post-myeloablative or reduced intensity as specified)
  2. For RegeneCyte: documentation of unrelated donor hematopoietic progenitor cell transplantation plan and appropriate preparative regimen
  3. Billing Rule

    Coding and Billing Note

    Coding guidance is informational and not a guarantee of coverage. Confirm current code updates before claim submission.

    • Informational codes: J3590 (Unclassified biologics) and C9399 (Unclassified drugs or biologicals)
    • Providers should reference the most up-to-date professional coding resources prior to billing
    Denial Risk

    Denial Triggers

    Claims may be denied if required criteria or documentation are missing or if the member does not meet age or indication requirements.

    • Denial triggers include: member below policy age thresholds, indication not consistent with policy criteria, lack of documentation of transplant plan or preparative regimen, and requests for more than the single administration specified
    • Inclusion or listing of codes in this policy does not guarantee coverage
    Regulatory context
    Omisirge (omidubicel) approved April 2023 as a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood; RegeneCyte approved November 2024 for unrelated donor hematopoietic progenitor cell transplantation in conjunction with an appropriate preparative regimen.
    Intended useProducts are intended for use in patients undergoing umbilical cord blood transplantation (Omisirge) or unrelated donor hematopoietic progenitor cell transplantation (RegeneCyte) for disorders affecting the hematopoietic system (inherited, acquired, or post‑myeloablative).